{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:06:41Z","timestamp":1763017601960},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jacl.2015.10.013","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T11:00:25Z","timestamp":1448967625000},"page":"228-239","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment"],"prefix":"10.1016","volume":"10","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.10.013_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","article-title":"Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel","volume":"148","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib2","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)","volume":"269","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.10.013_bib3","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2013.08.004","article-title":"The next steps in developing clinical practice guidelines for prevention","volume":"62","author":"Gibbons","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib6","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib7","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jamainternmed.2014.3278","article-title":"Prevention guidelines: bad process, bad outcome [editorial]","volume":"174","author":"Nissen","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib8","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib9","series-title":"Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline 181","year":"2014"},{"key":"10.1016\/j.jacl.2015.10.013_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib11","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.10.013_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia\u2014full report","volume":"8","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1\u2014full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5551\/jat.19166","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20142012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2015.10.013_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/bmj.303.6797.276","article-title":"Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations","volume":"303","author":"Chen","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2015.10.013_bib16","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib17","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib18","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc0707445","article-title":"A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction [letter]","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(86)90597-0","article-title":"Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men","volume":"2","author":"Martin","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.10.013_bib20","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.10.013_bib21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib22","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4065\/76.10.1039","article-title":"Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia","volume":"76","author":"Vella","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2015.10.013_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(99)00435-9","article-title":"Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia","volume":"150","author":"Raal","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.10.013_bib24","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.10.013_bib25","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.10.013_bib26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib27","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacl.2013.04.001","article-title":"Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association","volume":"7","author":"Bays","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jacc.2011.12.035","volume":"59","author":"Mora","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/clp.12.89","article-title":"Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment","volume":"8","author":"Orringer","year":"2013","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jacc.2013.07.045","article-title":"Non\u2013high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (Very Large Database of Lipids)","volume":"62","author":"Elshazly","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/CIRCULATIONAHA.113.007207","article-title":"Are we moving towards concordance on the principle that lipid discordance matters?","volume":"129","author":"Martin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.113.005873","article-title":"Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events","volume":"129","author":"Mora","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib34","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.10.013_bib35","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2014.10.002","article-title":"National Lipid Association Annual Summary of Clinical Lipidology 2015","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib37","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2337\/diacare.27.8.1991","article-title":"Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes","volume":"27","author":"Jiang","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2015.10.013_bib38","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1161\/01.CIR.0000146339.57154.9B","article-title":"Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines","volume":"110","author":"Shai","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MOL.0b013e32833ee80c","article-title":"Non-HDL C equals apolipoprotein B: except when it does not!","volume":"21","author":"Sniderman","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.atherosclerosis.2012.08.039","article-title":"Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study","volume":"225","author":"Sniderman","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.10.013_bib41","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","article-title":"Non\u2013high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality","volume":"161","author":"Cui","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non\u2013high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MOL.0000000000000178","article-title":"A comparison of European and US guidelines for familial hypercholesterolaemia","volume":"26","author":"Reiner","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib44","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.10.013_bib45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib46","unstructured":"QRISK Lifetime Cardiovascular Risk Calculator. Available at: http:\/\/www.qrisk.org\/lifetime\/index.php. Accessed April 6,\u00a02015."},{"key":"10.1016\/j.jacl.2015.10.013_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age","volume":"113","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib48","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.111.075929","article-title":"Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative","volume":"125","author":"Cook","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib49","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jama.2014.2632","article-title":"Comparison of application of the ACC\/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort","volume":"311","author":"Kavousi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.10.013_bib50","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.10.013_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000342765","article-title":"Cholesterol issues in Japan\u2013why are the goals of cholesterol levels set so low?","volume":"62","author":"Hamazaki","year":"2013","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.jacl.2015.10.013_bib52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/hc0302.102575","article-title":"Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular M\u00fcnster (PROCAM) study","volume":"105","author":"Assmann","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.10.013_bib53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1365-2362.2007.01888.x","article-title":"Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular M\u00fcnster (PROCAM) study","volume":"37","author":"Assmann","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2015.10.013_bib54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jacl.2014.09.009","article-title":"JCL roundtable: lipid-lowering drugs in those older than 75 years of age","volume":"8","author":"Brown","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.10.013_bib55","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1253\/circj.70.1249","article-title":"Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population","volume":"70","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2015.10.013_bib56","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)62388-0","article-title":"Statins: new American guidelines for prevention of cardiovascular disease","volume":"382","author":"Ridker","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.10.013_bib57","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.mayocp.2014.06.016","article-title":"A summary and critical assessment of the 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps","volume":"89","author":"Lopez-Jimenez","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2015.10.013_bib58","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1001\/jamainternmed.2014.5336","article-title":"Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study","volume":"174","author":"Cook","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib59","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.10.013_bib60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.mayocp.2014.06.018","article-title":"A perspective on the new American College of Cardiology\/American Heart Association guidelines for cardiovascular risk assessment","volume":"89","author":"Kullo","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2015.10.013_bib61","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.10.013_bib63","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.10.013_bib64","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415004444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415004444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T04:55:55Z","timestamp":1589604955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415004444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1933287415004444"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.10.013","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}